The market remains obsessed with headlines, politics, tariffs, inflation scares, wars, and whatever fresh catastrophe the internet's instant experts decide will end capitalism this week.



Meanwhile, some of the smartest and best-informed people in corporate America are quietly reaching into their own pockets and buying stock.



That matters.



Open-market buying by CEOs and CFOs has long been one of the most powerful signals in investing. Academic studies, hedge fund research, and decades of real-world market history all point toward the same conclusion:



When the people running a company voluntarily buy shares with after-tax dollars in the open market, future returns tend to outperform.



The signal becomes even more compelling when both the CEO and CFO buy at the same time.



The reason is straightforward. These are the two executives with the deepest understanding of the business.



The CEO sees:



<ul>
<li>Strategic trends</li>



<li>Customer demand</li>



<li>Competitive conditions</li>



<li>Long-term growth opportunities</li>
</ul>



The CFO sees:



<ul>
<li>Liquidity</li>



<li>Cash flow</li>



<li>Covenant conditions</li>



<li>Receivables</li>



<li>Margins</li>



<li>Financing costs</li>



<li>Operational realities</li>
</ul>



When both independently decide the stock is cheap enough to buy with personal capital, investors should pay attention.



Research from academic studies and firms specializing in insider activity has consistently shown that insider buying generates excess returns over subsequent 6- to 24-month periods. CFO buying may actually be the strongest insider signal of all because chief financial officers live inside the numbers every day. They often recognize improving business conditions long before Wall Street models catch up.



Insider selling is nowhere near as useful.



Executives sell stock for taxes, diversification, estate planning, college tuition, divorces, trust planning, and countless other reasons. Buying is different. There is usually only one reason executives voluntarily increase exposure to a stock they already own through compensation and career risk.



They think shares are going higher.



This month, several companies saw meaningful open-market buying from both CEOs and CFOs. These are exactly the kinds of situations Alpha Buying subscribers should monitor closely.



<hr/>



<h3>FTI Consulting – (NYSE:FCN)</h3>



FTI Consulting recently saw insider buying from both the CEO and CFO during May.



The consulting and construction management firm benefits from long-cycle trends tied to infrastructure spending, environmental remediation, restructuring activity, and government project work. These are businesses where management teams typically possess extraordinary visibility into future demand and contract pipelines.



Insider buying after a period of weakness suggests leadership believes the market is undervaluing the durability of future earnings growth and cash flow generation.



FTI has historically commanded premium valuations because of its operational consistency, making insider purchases especially noteworthy.



<hr/>



<h3>Option Care Health – (NASDAQ:OPCH)</h3>



Option Care Health experienced coordinated insider buying from both CEO John Rademacher and CFO Meenal Sethna following a significant decline in the stock price.



The company operates one of the nation's largest independent providers of home and alternate-site infusion therapy services. Demographic trends and the ongoing migration toward lower-cost outpatient care continue to provide powerful long-term tailwinds.



According to recent filings, the CEO purchased 12,500 shares while the CFO acquired more than 16,000 shares in May after the selloff intensified.



That type of buying activity following sharp weakness often signals management confidence that Wall Street has become overly pessimistic about temporary concerns.



<hr/>



<h3>Harrow Health – (NASDAQ:HROW)</h3>



Harrow Health also attracted insider buying from senior leadership, including both the CEO and CFO.



The ophthalmic pharmaceutical company continues benefiting from aging population trends and increasing demand for eye-care procedures and specialty medications. Harrow has steadily expanded its branded product platform and strengthened physician relationships across the ophthalmology market.



Insider purchases in healthcare companies are often especially meaningful because management teams possess far better visibility into:



<ul>
<li>Prescription trends</li>



<li>Reimbursement conditions</li>



<li>Physician demand</li>



<li>Pipeline developments</li>
</ul>



Coordinated buying from both the CEO and CFO suggests confidence that future operational momentum is stronger than current market sentiment implies.



<hr/>



<h3>GE HealthCare Technologies – (NASDAQ:GEHC)</h3>



GE HealthCare Technologies saw insider purchases from CEO Peter Arduini and CFO James Saccaro during May.



The company remains one of the premier franchises in diagnostic imaging, patient monitoring, and healthcare technology despite recent share-price weakness tied to broader healthcare sector concerns.



According to insider filings, both executives purchased shares in the open market rather than simply receiving stock grants as compensation.



That distinction matters.



Executives at companies this size already possess substantial equity exposure through compensation programs. Voluntarily adding shares with personal capital reflects genuine conviction rather than routine executive compensation.



For investors, that is a meaningful signal.



<hr/>



<h3>AECOM – (NYSE:ACM)</h3>



AECOM rounds out this month's list of companies seeing insider accumulation from both the CEO and CFO.



The global infrastructure consulting and engineering firm continues benefiting from multi-year spending programs tied to:



<ul>
<li>Transportation</li>



<li>Water systems</li>



<li>Environmental projects</li>



<li>Energy infrastructure modernization</li>
</ul>



Management has spent years reshaping the company toward higher-margin consulting operations while steadily improving free cash flow generation.



Insider buying suggests leadership sees continued strength ahead and believes the market is underestimating the durability of long-term infrastructure spending trends.



<hr/>



The broader lesson here is straightforward.



Markets fluctuate wildly based on narratives, emotions, positioning, and liquidity conditions.



Insiders operate in the real economy.



They see:



<ul>
<li>Orders</li>



<li>Invoices</li>



<li>Margins</li>



<li>Financing conditions</li>



<li>Customer behavior</li>
</ul>



long before that information appears in quarterly reports.



When both the CEO and CFO are buying stock at the same time — especially after periods of market weakness — the probabilities begin shifting in your favor.



It does not guarantee success. Nothing in markets does.



But history strongly suggests these situations deserve serious attention from disciplined investors willing to follow informed capital rather than emotional headlines.

GEHC

HROW

OPCH

Recent insider buying by CEOs and CFOs at several companies signals confidence in future stock performance. Notable examples include FTI Consulting, Option Care Health, Harrow Health, GE HealthCare Technologies, and AECOM, where both executives purchased shares, indicating they believe the stocks are undervalued. This trend suggests that management sees potential for growth despite current market pessimism, making these situations worth monitoring for investors.

benzinga_article

GE HealthCare Tech

Harrow

Option Care Health

Aecom

FTI Consulting

Harrow Health Pref Share HROWM 11.875 12/31/27

Harrow Health Pref Share HROWL 8.625 04/30/26

Alpha Buying: When CEOs and CFOs Buy Together